Skip to main content
. 2021 Oct 26;13(21):5373. doi: 10.3390/cancers13215373

Figure 8.

Figure 8

Model for the tumorigenic effects of TSPAN5 and the anti-tumorigenic effects of TSPAN5 depletion. DLC1 loss leads to increased TSPAN5 expression via MRTF-A transcriptional activation (left panel). Therapeutic knockdown of TSPAN5 results in OIS-induced inhibition of HCC growth via decreased actin polymerization and reduced MRTF/SRF target gene expression (right panel).